test

Phase III Randomized Study of Sorafenib Plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)(CALGB 80802)

Conditions

Liver

Trial Phase

Phase III

Trial Purpose and Description

Trial Purpose

Primary - Compare overall survival (OS) of patients treated with sorafenib and doxorubicin to that of those treated with sorafenib. Secondary - Compare time to progression (TTP) of patients treated with sorafenib and doxorubicin to that of those treated with sorafenib; compare progression-free-survival (PFS) of patients treated with sorafenib and doxorubicin to that of those treated with sorafenib; compare tumor response using RECIST criteria of patients treated with sorafenib and doxorubicin to that of those treated with sorafenib.


Participation Guidelines

Age:
Gender:

Eligibility Criteria

Sponsor:
CALGB
Dates:
05/07/2014
Last Updated:
Study HIC#:
1107008793